Home > others & > Sevelamer HCl

Sevelamer HCl

盐酸司维拉姆

Sevelamer hydrochloride是结合磷酸盐化合物，可用于高磷血症。

目录号
EY0680
EY0680
纯度
99.35%
99.35%
规格
100 mg
500 mg
原价
690
2600
售价
690
2600
库存
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Sevelamer HCl is a phosphate binding drug used to treat hyperphosphatemia via binding to dietary phosphate and prevents its absorption.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Cozzolino M, et al. Kidney Int, 2003, 64(5), 1653-1661.

    分子式
    C6H13Cl2NO    		 分子量
    186.08    		 CAS号
    152751-57-0    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    <1 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT01755078 Hemodialysis|Hyperphosphatemia|Cardiovascular Events Drug: Sevelamer HCl|Drug: Calcium-based phosphate binder Chugai Pharma Taiwan Phase 4 2007-06-01 2014-08-04
    NCT00267514 Chronic Kidney Disease Drug: sevelamer carbonate (Renvela庐) sevelamer hydrochloride (Renagel 庐)|Drug: sevelamer hydrochloride (Renagel 庐) sevelamer carbonate (Renvela庐) Genzyme, a Sanofi Company|Sanofi Phase 3 2006-01-01 2015-03-17
    NCT01543958 HIV-1 Infection Drug: Sevelamer carbonate|Device: Sevelamer carbonate AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 2011-11-01 2013-12-04
    NCT00756860 Healthy Volunteers Drug: AMG 223|Drug: Renagel庐 (sevelamer hydrochloride) Amgen Research (Munich) GmbH|Amgen Phase 1 2008-05-01 2012-05-31
    NCT01238588 Dialysis|Cardiovascular Disease|Atherosclerosis|Inflammation|Hyperphosphatemia Drug: Sevelamer Carbonate (Renvela) Brigham and Women's Hospital 2010-11-01 2015-10-05
    NCT00833768 Chronic Kidney Disease|Hyperphosphatemia Drug: Sevelamer carbonate|Drug: Placebo for sevelamer carbonate Genzyme, a Sanofi Company|Sanofi Phase 3 2009-01-01 2015-03-19
    NCT01191762 Hyperparathyroidism|Chronic Kidney Disease Drug: sevelamer carbonate|Drug: placebo Kenneth R. Phelps, M.D.|Genzyme, a Sanofi Company|Phelps, Kenneth R., M.D. Phase 3 2010-04-01 2016-09-26
    NCT00745589 Endstage Renal Disease Drug: sevelamer hydrochloride The University of Hong Kong 2008-07-01 2017-01-07
    NCT01574326 Hyperphosphatemia|Chronic Kidney Disease Drug: Placebo|Drug: Sevelamer carbonate Genzyme, a Sanofi Company|Sanofi Phase 2 2012-05-01 2016-06-14
    NCT00704483 Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy Drug: SBR759|Drug: Sevelamer HCl|Drug: SBR759|Drug: Sevelamer HCl Novartis Pharmaceuticals|Novartis Phase 2 2008-07-01 2016-11-16
    NCT00268957 Kidney Diseases|Chronic Renal Insufficiency|End-Stage Renal Disease Drug: Sevelamer carbonate (Renvela庐)|Drug: Sevelamer hydrochloride (Renagel庐) Genzyme, a Sanofi Company|Sanofi Phase 3 2006-01-01 2014-03-17
    NCT00837655 Kidney Failure, Chronic|End-Stage Renal Disease|Insulin Resistance|Hyperphosphatemia Drug: Sevelamer|Drug: Calcium carbonate Karolinska Institutet|G枚teborg University 2009-01-01 2012-09-25
    NCT02332811 Renal Failure Chronic Drug: sevelamer carbonate 800mg|Drug: sevelamer carbonate 2.4 g Genzyme, a Sanofi Company|Sanofi Phase 3 2013-10-01 2016-12-22
    NCT01011699 Chronic Renal Failure|Hemodialysis Drug: nicotinamide|Drug: sevelamer|Drug: cinacalcet Centre Hospitalier Universitaire, Amiens Phase 3 2010-01-01 2016-05-13
    NCT01135615 We Investigated the Relationship Between Plasma FGF23 Levels and Endothelial Dysfunction in a Sizable Series of Incident Stage 3-4 CKD Patients. Drug: Sevelamer|Drug: calcium acetate Gulhane School of Medicine Phase 4 2008-01-01 2011-07-20
    NCT01427907 Chronic Kidney Disease Drug: Calcium acetate oral solution (COS)|Drug: Sevelamer carbonate Fresenius Medical Care North America Phase 4 2011-09-01 2015-12-11
    NCT01220843 Chronic Renal Failure Drug: Placebo|Drug: Sevelamer carbonate Centre Hospitalier Universitaire, Amiens|Genzyme, a Sanofi Company Phase 3 2010-10-01 2016-04-27
    NCT00681941 Chronic Kidney Disease|Hyperphosphatemia Drug: Sevelamer carbonate (Renvela庐) Genzyme, a Sanofi Company|Sanofi Phase 3 2006-01-01 2015-03-19
    NCT00806481 Kidney Failure, Chronic|Cardiovascular Diseases Drug: Sevelamer carbonate|Drug: Placebo University Hospital Birmingham NHS Foundation Trust|Genzyme, a Sanofi Company Phase 2 2009-02-01 2011-11-22
    NCT02346890 Healthy Drug: AZD1722|Drug: Renvela Ardelyx|AstraZeneca Phase 1 2013-04-01 2015-01-26
    NCT03001011 Hyperphosphatemia Drug: Placebo|Drug: Sevelamer Carbonate (GZ419831) Sanofi Phase 3 2017-05-01 2016-12-21
    NCT01736150 Chronic Kidney Disease|Chronic Kidney Disease on Hemodialysis Drug: Placebo|Drug: Sevelamer carbonate Genzyme, a Sanofi Company|Sanofi Phase 3 2010-03-01 2015-03-19

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：